Dupixent (dupilumab) — Highmark
chronic spontaneous urticaria (CSU)
Initial criteria
- age ≥ 12 years
- diagnosis of urticaria classified as chronic spontaneous urticaria
- therapeutic failure, contraindication, or intolerance to one second-generation non-sedating H1 antihistamine at maximum recommended dose
Reauthorization criteria
- prescriber attests improvement in CSU symptoms
Approval duration
initial up to 6 months; reauthorization up to 12 months